DivestmentAug 4, 2026, 05:28 PM
Cumberland Divests Brands for $100M, Pays $1.50 Special Dividend
AI Summary
Cumberland Pharmaceuticals Inc. announced its Q2 2026 financial results and provided a company update following the successful closing of a strategic transaction. The company divested its portfolio of FDA-approved brands and commercial organization to Apotex Health for $100 million in cash, plus an additional $11 million. This transaction enabled Cumberland to return capital to shareholders through a special cash dividend of $1.50 per share and transition into a development-stage biopharmaceutical company. For Q2 2026, the company reported a net loss from continuing operations of $3.1 million and a total net loss of $4.1 million.
Key Highlights
- Completed strategic transaction with Apotex Health for $100 million cash plus $11 million for inventory and services.
- Divested portfolio of FDA-approved brands and related commercial organization to Apotex Health.
- Declared and paid a special cash dividend of $1.50 per share to shareholders.
- Transitioned into a development-stage biopharmaceutical company focused on rare diseases.
- Retained development pipeline, including four Phase 2 clinical programs, and majority ownership in Cumberland Emerging Technologies.
- Reported Q2 2026 net loss from continuing operations of $3.1 million.
- Reported Q2 2026 net loss of $4.1 million.
- Updated Phase 2 FIGHT DMD clinical trial results for ifetroban showed heart muscle protection.
Price Impact
More from CPIX